Pfizer Inc. (NYSE:PFE) Shares Sold by Wallace Capital Management Inc.

Wallace Capital Management Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 20.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,412 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Wallace Capital Management Inc.’s holdings in Pfizer were worth $223,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Rialto Wealth Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the fourth quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the 4th quarter worth $31,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer in the fourth quarter worth $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.8%

Shares of NYSE:PFE opened at $23.01 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $130.82 billion, a PE ratio of 16.32, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The firm has a fifty day moving average price of $23.60 and a 200 day moving average price of $25.28.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the firm posted $0.82 EPS. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.48%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.